Eric Joseph
Stock Analyst at JP Morgan
(1.97)
# 3,153
Out of 5,048 analysts
124
Total ratings
37.65%
Success rate
-7.22%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $34.05 | +43.91% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $22.88 | +101.05% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $60.72 | +5.41% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.39 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.36 | +1,209.52% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.64 | -8.32% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $68.31 | -1.92% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.38 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.61 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $12.24 | +145.10% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $5.29 | +164.65% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $58.77 | +20.81% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $19.32 | +96.69% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.70 | +521.62% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.02 | +111.97% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $6.87 | +205.90% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.15 | -10.31% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.26 | +1,090.48% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.31 | +159.74% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.13 | +94.93% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $12.14 | -9.35% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $54.04 | -24.13% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $16.46 | +507.72% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.59 | +749.33% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.21 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $17.25 | -36.23% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.34 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.54 | +2,066.06% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.35 | +3,984.41% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.86 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.46 | +518.56% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.14 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $3.69 | +1,038.21% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.82 | +616.25% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.56 | +1,868.50% | 3 | Nov 14, 2018 |
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $34.05
Upside: +43.91%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $22.88
Upside: +101.05%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $60.72
Upside: +5.41%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.39
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.36
Upside: +1,209.52%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.64
Upside: -8.32%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $68.31
Upside: -1.92%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $12.24
Upside: +145.10%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.29
Upside: +164.65%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $58.77
Upside: +20.81%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $19.32
Upside: +96.69%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $3.70
Upside: +521.62%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.02
Upside: +111.97%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $6.87
Upside: +205.90%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $11.15
Upside: -10.31%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.26
Upside: +1,090.48%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.31
Upside: +159.74%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.13
Upside: +94.93%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $12.14
Upside: -9.35%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $54.04
Upside: -24.13%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $16.46
Upside: +507.72%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.59
Upside: +749.33%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.21
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $17.25
Upside: -36.23%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $13.34
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.54
Upside: +2,066.06%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.35
Upside: +3,984.41%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $6.86
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.46
Upside: +518.56%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.14
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $3.69
Upside: +1,038.21%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.82
Upside: +616.25%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.56
Upside: +1,868.50%